Radioiodine Resensitization for Radioiodine Refractory Metastatic Differentiated Thyroid Cancer


( Last Updated : April 15, 2022)
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1419-000

Details


Question

  1. What is the clinical effectiveness of radioiodine resensitization followed by radioiodine in patients with radioiodine-refractory/resistant metastatic differentiated thyroid cancer?
  2. What is the cost-effectiveness of radioiodine resensitization followed by radioiodine in patients with radioiodine-refractory/resistant metastatic differentiated thyroid cancer?



Key Message

Evidence of radioiodine resensitization was reported in 4 single-arm clinical trials and 3 uncontrolled retrospective cohort studies, which included between 3 and 20 patients. Over half of patients in these 7 studies demonstrated increased radioiodine avidity after resensitization treatment.Where reported, at least half of radioiodine retreated patients remained progression free and/or had not initiated a new treatment by the end of study follow-up.Adverse events associated with radioiodine resensitization therapies were typically mild, with skin-related adverse events being most common.No studies comparing outcomes of radioiodine resensitization therapies against lenvatinib or to no treatment were identified.No evidence on the cost-effectiveness of radioiodine resensitization therapy was found.